Jeanne du Fay de Lavallaz

Jeanne du Fay de Lavallaz

Auto-generated profile, based on publicly available information

Jeanne du Fay de Lavallaz

University of Michigan Department of Cardiology Ann Arbor, MI

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2022 in Circulation
Verified
Journal Article
Open access
PDF file
JLJeanne du Fay de Lavallaz
Jeanne du Fay de Lavallaz
APAlexandra Prepoudis
Alexandra Prepoudis
MWMaria Janina Wendebourg
Maria Janina Wendebourg
EKEva Kesenheimer
Eva Kesenheimer
DKDiego Kyburz
Diego Kyburz
CMChristian Müller
Christian Müller
Background: Cardiac troponin (cTn) T and cTnI are considered cardiac specific and equivalent in the diagnosis of acute myocardial infarction. Previous studies suggested rare skeletal myopathies as a noncardiac source of cTnT. We aimed to confirm the reliability/cardiac specificity of cTnT in patients with various skeletal muscle disorders (SMDs). Methods: We prospectively enrolled patients presenting with muscular complaints (≥2 weeks) for elective evaluation in 4 hospitals in 2 countries. After a cardiac workup, patients were adjudicated into 3 predefined cardiac disease categories. Concentrations of cTnT/I and resulting cTnT/I mismatches were assessed with high-sensitivity (hs-) cTnT (hs-cTnT–Elecsys) and 3 hs-cTnI assays (hs-cTnI–Architect, hs-cTnI–Access, hs-cTnI–Vista) and compared with those of control subjects without SMD presenting with adjudicated noncardiac chest pain to the emergency department (n=3508; mean age, 55 years; 37% female). In patients with available skeletal muscle biopsies, TNNT/I1-3 mRNA differential gene expression was compared with biopsies obtained in control subjects without SMD. Results: Among 211 patients (mean age, 57 years; 42% female), 108 (51%) were adjudicated to having no cardiac disease, 44 (21%) to having mild disease, and 59 (28%) to having severe cardiac disease. hs-cTnT/I concentrations significantly increased from patients with no to those with mild and severe cardiac disease for all assays (all P <0.001). hs-cTnT–Elecsys concentrations were significantly higher in patients with SMD versus control subjects (median, 16 ng/L [interquartile range (IQR), 7–32.5 ng/L] versus 5 ng/L [IQR, 3–9 ng/L]; P <0.001), whereas hs-cTnI concentrations were mostly similar (hs-cTnI–Architect, 2.5 ng/L [IQR, 1.2–6.2 ng/L] versus 2.9 ng/L [IQR, 1.8–5.0 ng/L]; hs-cTnI–Access, 3.3 ng/L [IQR, 2.4–6.1 ng/L] versus 2.7 ng/L [IQR, 1.6–5.0 ng/L]; and hs-cTnI–Vista, 7.4 ng/L [IQR, 5.2–13.4 ng/L] versus 7.5 ng/L [IQR, 6–10 ng/L]). hs-cTnT–Elecsys concentrations were above the upper limit of normal in 55% of patients with SMD versus 13% of control subjects ( P <0.01). mRNA analyses in skeletal muscle biopsies (n=33), mostly (n=24) from individuals with noninflammatory myopathy and myositis, showed 8-fold upregulation of TNNT2 , encoding cTnT (but none for TNNI3 , encoding cTnI) versus control subjects (n=16, P Wald <0.001); the expression correlated with pathological disease activity ( R =0.59, P t-statistic <0.001) and circulating hs-cTnT concentrations ( R =0.26, P t-statistic =0.031). Conclusions: In patients with active chronic SMD, elevations in cTnT concentrations are common and not attributable to cardiac disease in the majority. This was not observed for cTnI and may be explained in part by re-expression of cTnT in skeletal muscle. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03660969.

1 March 2016 in International Journal of Cardiology
Verified
Journal Article
Closed access
TNThomas Nestelberger
Thomas Nestelberger
WKWildi Karin
Wildi Karin
JBJasper Boeddinghaus
Jasper Boeddinghaus
RTRaphael Twerenbold
Raphael Twerenbold
TRTobias Reichlin
Tobias Reichlin
CMChristian Müller
Christian Müller

1 May 2019 in International Journal of Cardiology
Verified
Journal Article
Closed access
WKWildi Karin
Wildi Karin
JBJasper Boeddinghaus
Jasper Boeddinghaus
TNThomas Nestelberger
Thomas Nestelberger
RTRaphael Twerenbold
Raphael Twerenbold
PBPatrick Badertscher
Patrick Badertscher
AEArnold von Eckardstein
Arnold von Eckardstein

2 November 2023 in EP Europace
Verified
Journal Article
Open access
PDF file
TSTeodor Serban
Teodor Serban
DMDiego Mannhart
Diego Mannhart
QAQurrat-Ul-Ain Abid
Qurrat-Ul-Ain Abid
AHAndres Höchli
Andres Höchli
SLSorin Lazar
Sorin Lazar
PBPatrick Badertscher
Patrick Badertscher
Aims: Pulmonary vein isolation (PVI) plays a central role in the interventional treatment of atrial fibrillation (AF). Uncertainties remain about the durability of ablation lesions from different energy sources. We aimed to systematically review the durability of ablation lesions associated with various PVI-techniques using different energy sources for the treatment of AF. Methods and results: Structured systematic database search for articles published between January 2010 and January 2023 reporting PVI-lesion durability as evaluated in the overall cohort through repeat invasive remapping during follow-up. Studies evaluating only a proportion of the initial cohort in redo procedures were excluded. A total of 19 studies investigating 1050 patients (mean age 60 years, 31% women, time to remap 2–7 months) were included. In a pooled analysis, 99.7% of the PVs and 99.4% of patients were successfully ablated at baseline and 75.5% of the PVs remained isolated and 51% of the patients had all PVs persistently isolated at follow-up across all energy sources. In a pooled analysis of the percentages of PVs durably isolated during follow-up, the estimates of RFA were the lowest of all energy sources at 71% (95% CI 69–73, 11 studies), but comparable with cryoballoon (79%, 95%CI 74–83, 3 studies). Higher durability percentages were reported in PVs ablated with laser-balloon (84%, 95%CI 78–89, one study) and PFA (87%, 95%CI 84–90, 2 studies). Conclusion: We observed no significant difference in the durability of the ablation lesions of the four evaluated energies after adjusting for procedural and baseline populational characteristics.

2 July 2024 in EP Europace
Verified
Journal Article
Open access
TATolga Aksu
Tolga Aksu
RPRoman Piotrowski
Roman Piotrowski
RTRoderick Tung
Roderick Tung
TPTom De Potter
Tom De Potter
TMTimothy M Markman
Timothy M Markman
HHHenry D. Huang
Henry D. Huang
Aims: Prior case series showed promising results for cardioneuroablation in patients with vagally induced atrioventricular blocks (VAVBs). We aimed to examine the acute procedural characteristics and intermediate-term outcomes of electroanatomical-guided cardioneuroablation (EACNA) in patients with VAVB. Methods and results: This international multicentre retrospective registry included data collected from 20 centres. Patients presenting with symptomatic paroxysmal or persistent VAVB were included in the study. All patients underwent EACNA. Procedural success was defined by the acute reversal of atrioventricular blocks (AVBs) and complete abolition of atropine response. The primary outcome was occurrence of syncope and daytime second- or advanced-degree AVB on serial prolonged electrocardiogram monitoring during follow-up. A total of 130 patients underwent EACNA. Acute procedural success was achieved in 96.2% of the cases. During a median follow-up of 300 days (150, 496), the primary outcome occurred in 17/125 (14%) cases with acute procedural success (recurrence of AVB in 9 and new syncope in 8 cases). Operator experience and use of extracardiac vagal stimulation were similar for patients with and without primary outcomes. A history of atrial fibrillation, hypertension, and coronary artery disease was associated with a higher primary outcome occurrence. Only four patients with primary outcome required pacemaker placement during follow-up. Conclusion: This is the largest multicentre study demonstrating the feasibility of EACNA with encouraging intermediate-term outcomes in selected patients with VAVB. Studies investigating the effect on burden of daytime symptoms caused by the AVB are required to confirm these findings.

1 November 2018 in International Journal of Cardiology
Verified
Journal Article
Closed access
WKWildi Karin
Wildi Karin
HSH. Singeisen
H. Singeisen
RTR. Twerenbold
R. Twerenbold
PBP. Badertscher
P. Badertscher
DWDesiree Nadine Wussler
Desiree Nadine Wussler
CMC. Mueller
C. Mueller